다우존스 지수

같은 생각을 가진 투자자들과 토론할 수 있는 활발한 포럼에서 상호 작용하려면 등록하세요.

등록

홈
인베스팅
주식
미국
NASDAQ
AcelRX Pharmaceuticals Inc (ACRX)
AcelRX Pharmaceuticals Inc (ACRX) 뉴스

ACRX

AcelRX Pharmaceuticals (ACRX)

AcelRX Pharmaceuticals Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:ACRX

1 2 3 4 5 6 7 8 9 10 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/04/30	05:25	Edgar (US Regulatory)	Form ARS - Annual Report to Security Holders	NASDAQ:ACRX	AcelRX Pharmaceuticals Inc
2024/04/30	05:24	Edgar (US Regulatory)	Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material	NASDAQ:ACRX	AcelRX Pharmaceuticals Inc
2024/04/30	05:23	Edgar (US Regulatory)	Form DEF 14A - Other definitive proxy statements	NASDAQ:ACRX	AcelRX Pharmaceuticals Inc
2024/04/20	05:37	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ACRX	AcelRX Pharmaceuticals Inc
2024/03/22	05:30	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ACRX	AcelRX Pharmaceuticals Inc
2024/03/16	05:01	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ACRX	AcelRX Pharmaceuticals Inc
2024/03/13	07:39	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ACRX	AcelRX Pharmaceuticals Inc
2024/01/09	23:17	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ACRX	AcelRX Pharmaceuticals Inc
2024/01/09	23:05	PR Newswire (US)	AcelRx Announces Rebranding With Name Change to Talphera, Inc.	NASDAQ:ACRX	AcelRX Pharmaceuticals Inc
2023/12/14	22:11	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ACRX	AcelRX Pharmaceuticals Inc
2023/12/14	06:34	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ACRX	AcelRX Pharmaceuticals Inc
2023/12/14	06:25	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ACRX	AcelRX Pharmaceuticals Inc
2023/12/12	22:30	PR Newswire (US)	AcelRx Pharmaceuticals Announces Publication of Study Evaluating Anticoagulation Practices for Continuous Renal Replacement Therapy in the United States	NASDAQ:ACRX	AcelRX Pharmaceuticals Inc
2023/12/01	14:15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:ACRX	AcelRX Pharmaceuticals Inc
2023/11/23	06:38	Edgar (US Regulatory)	Form S-3 - Registration statement under Securities Act of 1933	NASDAQ:ACRX	AcelRX Pharmaceuticals Inc
2023/11/23	06:34	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:ACRX	AcelRX Pharmaceuticals Inc
2023/11/14	20:07	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:ACRX	AcelRX Pharmaceuticals Inc
2023/11/09	06:14	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ACRX	AcelRX Pharmaceuticals Inc
2023/11/09	06:05	PR Newswire (US)	AcelRx Reports Third Quarter 2023 Financial Results and Provides Corporate Update	NASDAQ:ACRX	AcelRX Pharmaceuticals Inc
2023/11/08	06:05	PR Newswire (US)	AcelRx to Host KOL Panel Discussion on Current Anticoagulant Use in Dialysis and the Upcoming Niyad™ Clinical Study	NASDAQ:ACRX	AcelRX Pharmaceuticals Inc
2023/10/27	05:30	PR Newswire (US)	AcelRx to Host Third Quarter 2023 Financial Results Call and Webcast on November 8, 2023	NASDAQ:ACRX	AcelRX Pharmaceuticals Inc
2023/10/21	05:30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ACRX	AcelRX Pharmaceuticals Inc
2023/10/11	05:17	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ACRX	AcelRX Pharmaceuticals Inc
2023/10/06	05:45	Edgar (US Regulatory)	Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material	NASDAQ:ACRX	AcelRX Pharmaceuticals Inc
2023/10/06	05:30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ACRX	AcelRX Pharmaceuticals Inc
2023/10/03	21:30	PR Newswire (US)	AcelRx Receives IDE Approval for Niyad and Advances to a Single Registration Study	NASDAQ:ACRX	AcelRX Pharmaceuticals Inc
2023/09/23	06:18	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ACRX	AcelRX Pharmaceuticals Inc
2023/09/12	08:13	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ACRX	AcelRX Pharmaceuticals Inc
2023/09/06	21:30	PR Newswire (US)	AcelRx Pharmaceuticals to Participate in the H.C. Wainwright Annual Investment Conference	NASDAQ:ACRX	AcelRX Pharmaceuticals Inc
2023/08/28	19:35	Edgar (US Regulatory)	Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material	NASDAQ:ACRX	AcelRX Pharmaceuticals Inc

검색 관련기사 보기:NASDAQ:ACRX

1 2 3 4 5 6 7 8 9 10 다음 >>

Proxim Wireless (CE)

TecDAX Kursindex

FC Porto Fan Token

iShares S&P 500 Value ETF

Experience Investment

Doccheck Aktiengesellsch...

Advantage Energy

Jardine Matheson (PK)

Delayed Upgrade Clock

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관